Company / R&D Expense
AMICUS THERAPEUTICS, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$135.8M
FY2025
5-year range
$109.4M / $276.7M
FY2021-FY2025
Trend
+24.2%
vs FY2024
Sector context
#114 of 210
Health Care
What the data says
At $136M, AMICUS THERAPEUTICS, INC.'s r&d expense ranks #114 of 210 in the Health Care sector. R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $136M.
Based on SEC 10-K filings.
$136M in FY2025 with a 5-year CAGR of -15.1%.
Declined from $152M to $136M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -21.1%
- 5-Year CAGR
- -15.1%
- 10-Year CAGR
- -
Sector benchmark
#114 of 210 in Health CareTop 54% of 210This company $135.8M Sector average $644.1M
▼
-78.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.1%, indicating a declining trend.
- In FY2025, r&d expense increased 24.2% year-over-year.
- Ranks #114 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $135.8M | +24.2% |
| FY2024 | $109.4M | -28.2% |
| FY2023 | $152.4M | -44.9% |
| FY2022 | $276.7M | +1.7% |
| FY2021 | $272.0M | -11.8% |
| FY2020 | $308.4M | +7.7% |
| FY2019 | $286.4M | +5.7% |
| FY2018 | $270.9M | +81.4% |
| FY2017 | $149.3M | +42.5% |
| FY2016 | $104.8M | +36.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026